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Abstract
Introduction: There have been few studies about gene differences between patients with diffuse-type gastric cancer and those
with intestinal-type gastric cancer. The aim of this study was to compare the transcriptomes of signet ring cell gastric cancer
(worst prognosis in diffuse-type) and well-differentiated gastric cancer (best prognosis in intestinal-type); NUDC was identified,
and its prognostic role was studied. Materials and Methods: We performed next-generation sequencing with 5 well-
differentiated gastric cancers and 3 of signet ring cell gastric cancer surgical samples. We performed gene enrichment and
functional annotation analysis using the Database for Annotation, Visualization and Integrated Discovery bioinformatics
resources. Immunohistochemistry was used to validate NUDC expression. Results: Overall, 900 genes showed significantly
higher expression, 644 genes showed lower expression in signet ring cell gastric cancer than in well-differentiated gastric cancers,
and there was a large difference in adhesion, vascular development, and cell-to-cell junction components between the 2 subtypes.
We performed variant analysis and found 52 variants and 30 cancer driver genes, including NUDC. We analyzed NUDC
expression in gastric cancer tissue and its relationship with prognosis. Cox proportional hazard analysis identified T stage, N stage,
and NUDC expression as independent risk factors for survival (P < 0.05). The overall survival of the NUDC-positive group was
significantly higher (53.2 + 0.92 months) than that of the NUDC-negative group (44.6 + 3.7 months) (P¼ 0.001) in Kaplan-Meier
survival analysis. Conclusion: We found 30 cancer driver gene candidates and found that the NUDC-positive group showed
significantly better survival than the NUDC-negative group via variant analysis.
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Gastric cancer is the sixth most common cancer worldwide and
remains the second leading cause of death by global cancer
statistics 2018.1 The standard of care for stage I stomach cancer
is surgery alone, but patients with stage II or III disease
undergo surgery with adjuvant chemotherapy. Historically, sto-
mach cancer was microscopically classified by Lauren’s clas-
sification as intestinal-type gastric adenocarcinoma (IGC) or
diffuse-type gastric adenocarcinoma (DGC), and this classifi-
cation system is still widely used.2 IGC results in a tumor with
maintained gland shape and is often associated with intestinal
metaplasia. However, DGC results in a mass or an infiltrating
pattern and does not form glands, and tumor cells infiltrate the
stroma as single cells or small cell groups.3
The etiologies of the 2 types of cancer are different. IGC is
believed to develop from the evolution of a precancerous
lesion, which was reported by Dr. Correa.4,5 Chronic gastritis
develops into intestinal metaplasia, dysplasia, and adenocarci-
noma, and Helicobacter pylori has been reported as a factor. In
contrast, there is no hypothesized theory for how DGC devel-
ops, but hereditary diffuse-type gastric cancer has been
reported to be caused by hereditary E-cadherin (CDH1) dele-
tion in New Zealand.6 The detection rate of E-cadherin muta-
tions in Maori families with hereditary gastric cancer is
reported to be up to 30%, and in individuals with such muta-
tions, most cases of stomach cancer (less than 70%) occur by
the age of 80. The incidence rate of signet ring cell gastric
cancer (SRC-GC) among DGC cases is known to be approxi-
mately 8% to 30%.7,8 Signet ring cells have a small nucleus on
one side, the cytoplasm is full of mucus, and rarely forms a line
or coronary structure.9 Although the Lauren classification is
traditionally used, the World Health Organization (WHO) clas-
sification is considered more objective. SRC-GC is classified
as a positive subtype in the WHO classification.10 The prog-
nosis of SRC-GC is better than that of other types of gastric
cancer when detected and treated early; however, when the
cancer is progressive, the cancer cells tend to invade, and
lymph node metastasis is generally high, resulting in a poorer
prognosis than those of other types of gastric cancer.7 Gene
analysis between the subtypes is needed to identify the phe-
nomena associated with different prognoses of DGC than IGC.
The survival and progression of gastric adenocarcinoma are
not only clearly different in terms of gross and molecular sub-
type; there have been a few studies about gene differences
between IGC and DGC.11 Specifically, there have been few
studies about gene differences between patients with diffuse-
type gastric cancer and those with intestinal-type gastric can-
cer. The aim of this study was to compare the transcriptomes of
signet ring cell gastric cancer (SRC-GC; worst prognosis in
diffuse-type) and well-differentiated gastric cancer (WD-GC,
best prognosis in intestinal-type); from our experiments,
nuclear distribution protein (NUDC) was identified.
NUDC is related to the nudC gene of the filamentous fungus
Aspergillus nidulans, which is essential for the movement of
nuclei following mitosis and for colony growth. Human NUDC
is important in not only normal hematopoietic cells but also
malignant hematopoietic precursors.12,13 NUDC overexpres-
sion has been reported in several cancers, but there has
been little research on the influence of NUDC on stomach
cancer.14-18 We conducted a survival analysis and investigated
the role of NUDC in gastric cancer patients.
Materials and Methods
Ethics Approval
This study was designed and carried out according to the prin-
ciples of the Declaration of Helsinki (1989). Written consent
was obtained from all participants before inclusion in the trial.
The study was approved by the Institutional Review Board
of Gyeongsang National University Hospital (GNUHIRB
2009-54).
RNA Extraction and Next-Generation Sequencing
We collected surgical stomach cancer tissue samples from 9
patients who underwent surgical operations between 2012 and
2015. Frozen tissue from patients who agreed to preoperative
tissue collection was stored in a 70C deep freezer.
We choose 4 SRC-GC and 5 WD-GC cases. The cancer
tissue was cut into 5 mm sections, and H&E staining was per-
formed. H&E-stained slides were used to identify the morphol-
ogy and location of gastric cancer tissue within normal gastric
tissue. Afterward, the remaining tissue was cut at 10-20 mm
thickness. We performed tissue collection by laser capture
microdissection (LCM; Veritas LCM2110, Molecular Device
Corporation, CA, USA) and compared these slides with the
H&E slides (Figure 1A-C) according to the manufacturer’s
recommendations. After tissue collection, we extracted RNA
using a Total Purification Kit (Norgene Bioteck Corp, Thorold,
Ontario, Canada) according to the manufacturer’s
recommendations.
We collected 9 surgical samples in total, 6 WD-GC samples
and 3 SRC-GC samples, and we found that 1 WD-GC sample
was severely degraded. Ultimately, we compared 5 WD-GC
samples with 3 SRC-GC samples (Figure 1D-F). We performed
transcriptome sequencing, and we compared expression pro-
files between clinically comparable samples using transcrip-
tome resequencing data. mRNA sequencing was performed
with next-generation sequencing technology by Macrogen, Inc.
(Seoul, Republic of Korea). We performed gene enrichment
and functional annotation analysis using the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
bioinformatics resources (https://david.ncifcrf.gov) with the
Ingenuity Pathway Analysis system (Qiagen, Hilden, Ger-
many), and we determined the top 10 different genes in terms
of the biologic process, cellular component, and molecular
function categories and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway differences between SRC-GC and
WD-GC (Figure 2).19
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We generated a schematic illustration of the results of the
cancer driver variant analysis. We filtered 170,602 variants and
16,460 genes, and we ultimately extracted 52 variants and 30
cancer driver genes. We performed variant analysis and net-
work analysis with Insilicogen Inc. software (Yongin-si,
Korea). We found 16,460 genes with 170,602 variants by com-
paring IGC (A group) and DGC (B group) samples. The genes
were filtered by the 1000 Genomes Project, ExAC, NHLBI
ESP exomes (with the parameters African American and Eur-
opean American), and Allele Frequency Community (with the
parameters common variants and allele frequency below 0.1)
resources. Common variants were filtered to include only
pathogenic variants (according to the ACMG guidelines clas-
sification). We selected more than 2/3 of the samples in the
SRC-GCB group and more than 2/5 of the samples in the WD-
GC group and filtered the results by biological context (metas-
tasis, signet ring adenocarcinoma or signet ring cell primary
gastric adenocarcinoma). Finally, we found cancer driver var-
iants with a frequency greater than 0.01% in the COSMIC and
TCGA databases (Figure 3; Table 1).
Validation of NUDC Expression by Tissue Microarray
Analysis and Immunohistochemistry
We generated a tissue microarray with surgical samples from
313 patients and collected clinical data from the patients’
pathological reports regarding cancer recurrence. In the case
of death, the National Statistical Office of the Republic of
Korea was commissioned for confirmation.
Immunohistochemistry staining of NUDC was performed
using monoclonal anti-rabbit NUDC antibody (1:300; Abcam,
Boston, MA, USA). For immunohistochemical staining,
unstained slides were treated with 3% H2O2 after deparaffini-
zation and rehydration. After heating the slides in a microoven
to induce epitope expression, we performed immunohisto-
chemical staining by using the UltraVision LP detection system
(Lab Vision Corporation, Fremont, CA, USA). The expression
of NUDC was scored by a pathologist blinded to the clinico-
pathological data. Cytoplasmic reactions were scored accord-
ing to the percentage of NUDC-positive cells as follows: 0,
negative, 1þ (1%-24%), 2þ (25%-49%), and 3þ (50%-74%)
(Figure 4).
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics
24.0 software (IBM Corporation, Somers, NY, USA). Data
represents the mean + SD. The significance of the difference
was determined by w2 test, Student’s t-test, and Cox propor-
tional hazard analysis. The Kaplan-Meier method was used to
analyze patient overall survival. Statistical tests were either 2-
sided or 1-sided, and P  0.05 was considered statistically
significant.
Figure 1. We collected surgical samples by laser capture microdissection (LCM, A-C), and we compared expression profiles using tran-
scriptome resequencing data (D-F). A, LCM machine (Veritas LCM2110). B, Placement of the cap. B’, shows each captured cap. C, LCM
process. D, Multidimensional scaling plot. E, Heat map for hierarchical clustering. F, Significant count by fold change and P-value.
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Figure 3. Schematic illustration of the results of the cancer driver variant analysis. We filtered 170,602 variants and 16,460 genes, and we
ultimately extracted 52 variants and 30 cancer driver genes.
Figure 2. We performed gene enrichment and functional annotation analysis using the DAVID database, and the top 10 differentially expressed
genes in the biological process, cellular component, and molecular function categories and the KEGG pathway differences between signet ring
cell gastric adenocarcinoma and well-differentiated gastric adenocarcinoma are shown. DAVID, Database for Annotation, Visualization and
Integrated Discovery; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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Results
Comparison of the Transcriptome Between SRC-GC and
WD-GC
We performed next-generation sequencing on 3 SRC-GC and 5
WD-GC samples. We compared the 2 groups with multidimen-
sional scaling and found that SRC-GC and WD-GC samples
showed clear differences (Figure 1D), including clear differ-
ences in the 2-dimensional heatmap for hierarchical clustering
(Figure 1E). We performed statistical analysis, and we found
that 900 genes showed significantly higher expression and 644
genes showed lower expression in SRC-GC than in WD-GC
(Figure 1F).
To identify differences in gene ontology (GO), we per-
formed gene enrichment and functional annotation analysis
using DAVID, and we identified the top 10 different genes in
the biological process, cellular component, and molecular
function categories and KEGG pathway differences between
IGC and DGC, and the results are shown in Figure 2.
For the genes in the biological process category, the genes with
the largest differences between SRC-GC and WD-GC were
related to biological adhesion and cell adhesion. Cytoskeletal
organization, vascular development and blood vessel develop-
ment were also different between the 2 groups. Regarding the
cellular component category, the plasma membrane, plasma
membrane part, cytoskeleton, cell junction basolateral plasma
Table 1. The Important 30 Cancer Driver Genes List Between Signet Ring Cell Type Gastric Adenocarcinoma and Well Differentiated Type
Gastric Adenocarcinoma.







AATF Apoptosis antagonizing transcription factor Nucleus Transcription regulator 2 3 1
ALMS1 ALMS1, centrosome and basal body
associated protein
Cytoplasm Other 1 2 0
CDC14B Cell division cycle 14B Nucleus Phosphatase 1 2 1
CHFR Checkpoint with forkhead and ring finger
domains, E3 ubiquitin protein ligase
Nucleus Enzyme 1 2 0
DOCK1 Dedicator of cytokinesis 1 Cytoplasm Other 2 2 0
DYNC1H1 Dynein, cytoplasmic 1, heavy chain 1 Cytoplasm Peptidase 1 2 0
EIF2AK3 Eukaryotic translation initiation factor 2
alpha kinase 3
Cytoplasm Kinase 1 2 1
FBLN5 Fibulin 5 Extracellular Space Other 1 2 0
FLNA Filamin A Cytoplasm Other 2 3 1
H3F3C H3 histone, family 3C Other Other 1 2 0
HLA-C Major histocompatibility complex, class I, C Plasma Membrane Other 1 3 0
HLA-DQA2 Major histocompatibility complex, class II,
DQ alpha 2
Plasma Membrane Transmembrane receptor 4 2 1
HNRNPM Heterogeneous nuclear ribonucleoprotein M Nucleus Other 2 2 1
IFT74 Intraflagellar transport 74 Cytoplasm Other 1 2 0
LGALS9B Lectin, galactoside-binding, soluble, 9B Cytoplasm Other 2 2 1
MOV10L1 Mov10 RISC complex RNA helicase like 1 Nucleus Enzyme 1 2 0
MUSK Muscle, skeletal, receptor tyrosine kinase Plasma Membrane Kinase 2 2 0
NFKB1 Nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1
Nucleus Transcription regulator 1 2 0
NUDC NudC nuclear distribution protein Cytoplasm Other 1 2 0
PDE4D Phosphodiesterase 4D Cytoplasm Enzyme 2 2 0
PHLPP1 PH domain and leucine rich repeat protein
phosphatase 1
Cytoplasm Enzyme 1 2 0
PICALM Phosphatidylinositol binding clathrin
assembly protein
Cytoplasm Other 1 2 1
PLA2G4A Phospholipase A2 group IVA Cytoplasm Enzyme 1 2 0
PTPRS Protein tyrosine phosphatase, receptor
type S
Plasma Membrane Phosphatase 2 2 0
RGPD4 RANBP2-like and GRIP domain
containing 5
Nucleus Other 6 3 3
SEMA4D Semaphorin 4D Plasma Membrane Transmembrane receptor 1 2 0
SOS2 SOS Ras/Rho guanine nucleotide exchange
factor 2
Cytoplasm Other 1 2 0
SPAST Spastin Nucleus Enzyme 2 3 1
TBC1D3 TBC1 domain family member 3 Extracellular Space Other 1 2 1
ZNF267 Zinc finger protein 267 Nucleus Other 6 2 1
Abbreviations: SRC-GC, signet ring cell gastric cancer; WD-GC, well-differentiated gastric cancer.
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membrane and cell-cell junction terms were significantly differ-
ent between the 2 groups. Regarding the molecular function
category, the cytoskeletal protein binding, actin binding,
nucleoside-triphosphate regulator activity, GTPase regulator activ-
ity, and carbohydrate binding terms were significantly different
between the 2 groups. In the KEGG pathway analysis, the focal
adhesion, MAPK signaling pathway, regulation of actin cytoske-
leton, endocytosis, ECM-receptor interaction, and cell adhesion
molecule terms were significantly different between the 2 groups.
We performed variant analysis between the SRC-GC and
WD-GC groups, and we found 170,602 variants among 16,460
genes (Figure 3). We identified which of these variants and
genes were associated with pathologic variants with a fre-
quency of more than 0.01% using a public database, and we
ended up with 52 variants and 30 genes (Table 1). In terms of
intracellular location, 13 of the 30 genes, including ALMS1,
DOCK1, NUDC, and PHLPP1, were located in the cytoplasm,
9 genes, including AATF and NFKB, were located in the
nucleus, 5 genes, including SEMA4D and MLA-C, were
located in the plasma membrane, and 2 genes, FBLN5 and
TBC1D3, were located in the extracellular space. In terms of
the type of protein encoded by the gene, PPHLPP1, CHFR,
PDE4D, PLA2G4A, and MOV10L1 encode enzymes, and
EIP2AK3 and MISK encode kinases. AATF and NFKB1 are
transition regulators, CDC14B and PTPRS are phosphatases,
and DYNC1H1 is a peptidase.
The NUDC-Positive Group Showed Better Survival Than
the NUDC-Negative Group
NUDC was identified among the 30 cancer driver genes, and
we analyzed NUDC expression in gastric cancer tissue and its
relationship with clinical prognosis. We scored NUDC expres-
sion in gastric cancer samples (n ¼ 313) using immunohisto-
chemistry, as shown in Figure 2, and we divided samples with a
staining score over 1þ-3þ into the NUDC-positive group and
those with a staining score of 0 into the NUDC-negative group
to analyze clinicopathological factors.
The mean age of the patients was 63.0 + 10.8 years, and
more patients were male than female (M/F: 203/110). Accord-
ing to the WHO classification, the most common phenotype
was moderately differentiated (n ¼ 109), followed by poorly
differentiated (n ¼ 102), well differentiated (n ¼ 61), and
signet ring cells (n ¼ 27). The intestinal type was more com-
mon (n ¼ 169) than the diffuse type (n ¼ 61) or mixed type (n
¼ 11). The mean tumor size was 4.5 + 2.8 cm, and early T
stage (T1/2/3/4: 149/33/95/36), no lymph node metastasis (N0/
1/2/3: 18,844/37/41/51), no distant metastasis (M0/1: 311/2),
and early TNM stage (stage I/II/III/IV: 166/58/87/2) were the
most common characteristics. In terms of NUDC expression,
NUDC positivity was more common than NUDC negativity
(NUDC 0/1/2/3: 28/113/107/65) (Supplement Table 1).
We performed Cox proportional hazard analysis of clinico-
pathological features and NUDC expression, and we found that
Figure 4. Immunohistochemical analysis of NUDC expression in gastric carcinoma tissues. Staining of NUDC was performed using anti-NUDC
antibody cytoplasmic reactions were scored according to the percentage of NUDC-positive cells as follows: 0, negative, 1þ (1%-24%), 2þ
(25%-49%), and 3þ (50%-74%). Arrows show representative cells with positive staining for NUDC.
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tumor stage (T1 vs T2-4), lymph node status (N0 vs N 1), and
NUDC expression (negative vs. positive) were independent
risk factors for survival (P < 0.05). However, there were no
differences in age, sex, WHO class, metastasis, or
chemotherapy. In terms of tumor stage, the hazard ratio of the
T2-4 group was 3.68 times higher than that of the T1 stage
group (95% CI, 1.33-10.01, P¼ 0.012). In terms of lymph node
status, the hazard ratio of the N  1 group was 9.22 times
higher than that of the N0 group (95% CI 3.8-22.2, P <
0.001). In terms of NUDC expression, the hazard ratio of the
NUDC-negative group was 2.44 times higher than that of the
NUDC-positive group (95% CI 1.27-4.69) (Table 2).
We performed Kaplan-Meier survival analysis according to
NUDC expression. Figure 5A shows each overall survival
curve according to NUDC expression (negative, 1, 2, and 3
(P¼ 0.008)). The overall survival of the NUDC-positive group
was significantly higher (53.2 + 0.92 months, 95% CI, 51.4-
55.0 months) than that of the NUDC-negative group (44.6 +
3.7 months, 95% CI, 37.3-51.9 months) (P ¼ 0.001)
(Figure 5B).
Discussion
The aim of this study was to compare the transcriptomes of 2
very different subtypes of gastric cancer (SRC-GC and WD-
GC). We found that there was a large difference in adhesion,
vascular development, and cell-to-cell junction components,
and we also conducted cancer variable analysis. We found 30
cancer driver gene candidates. We found that the NUDC-
positive group showed significantly better survival than the
NUDC-negative group, as determined by transcriptome variant
analysis.
Collecting fresh RNA is difficult during cancer surgery
because ischemia has already occurred. Even if the procedure
is performed quickly after resection and the surgical procedure
mainly uses vessel ligation, RNA degradation is inevitable
during surgery.20 Additionally, most biopsies are performed
in advanced cancer, and there is so much inflammation and
fibrosis around the tumor mass that it is not easy to distinguish
Table 2. Cox Proportional Hazard Analysis by Clinicopathological







Age < 70 0.121 Reference
 70 1.51 0.89-2.56










Tumor EGC (T1) 0.012 Reference
AGC (T2-4) 3.68 1.33-10.01
Lymph node No (N0) <0.001 Reference
Yes (N  1) 9.22 3.8-22.2
Metastasis No (M ¼ 0) 0.182 Reference
Yes (M ¼ 1) 2.78 0.61-12.5




Negative (score 0) 0.007 2.44 1.27-4.69
Positive (score 1-3) Reference
Abbreviations: NUDC, nuclear distribution protein C; WHO, World Health
Organization; WD, well differentiated; MD, moderately differentiated; PD,
poorly differentiated; SRC, signet ring cell carcinoma; LN, lymph node; EGC,
early gastric cancer; AGC, advanced gastric cancer.
aValues in boldface indicate the significance of the differences determined
using the Student’s unpaired T-test.
Figure 5. Patients with NUDC overexpression showed longer survival times than patients with NUDC underexpression in the Kaplan-Meier
survival analysis. A, Overall survival according to NUDC expression (negative to 3). B, Overall survival of the NUDC-positive and NUDC-
negative groups.
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between cancer, fibrotic, and inflamed tissue with the naked
eye. Therefore, if next-generation sequencing is performed
using tissue, at least H&E staining should also be performed
to confirm that the tissue is cancerous. We performed LCM, but
for the DGC samples, we thought that there might be muscle
tissue contamination because diffuse cancers mostly invade
nearby tissues, especially gastric muscle.21 Therefore, there
have been few reports studying whole transcriptomes in gastric
cancer.
Recently, a transcriptome sequencing study of SRC-GCs vs
non-SRC-GCs was reported.11 The researchers conducted the
study to identify key mRNAs and signaling pathways and the
transcriptome in SRC-GC, and gene expression was analyzed
by comparing 30 SRC-GS samples and 30 non-SRC-GC sam-
ples. MAGEA2, MEGA3, MEGA4, MEGS5 (cancer-testis
antigens) and regenerating islet derived 1 beta (REG1B)
showed differences between the 2 groups. Fifteen KEGG path-
ways were reported, including the Rap1 signaling pathway and
the EGFR tyrosine kinase inhibitor resistance pathway. The
endocytosis pathway was also differentially activated between
the 2 groups in this study. We found that the terms adhesion,
cytoskeleton, vascular development, and blood vessel develop-
ment were enriched in SRC-GCs compared with WD-GCs in
the DAVID analysis. SRC-GCs have some components of
DGC, and they are known to have greater adherence to sur-
rounding tissues during invasion and greater inflammation than
IGCs. These characteristics are one reason why most samples
are identified as advanced stage samples, and advanced cancer
has central necrosis with peripheral inflammation. As such, the
tumors need to be dissected by LCM. Many molecular function
terms, such as cytoskeletal protein, actin, and GTP, can also be
related to the invasive and adhesive characteristics of DGCs.
On the other hand, IGCs tend to form glands and have limited
inflammation and adhesion to surrounding tissues. The concept
of our study, which compared transcriptomes, was similar to
that of Zhao et al’s study,11 but the control groups were differ-
ent. They compared SRC-GCs and poorly differentiated GCs,
which are both DGCs, but we compared SRC-GCs (DGCs) and
WD-GCs (IGCs). Additionally, the number of next-generation
sequencing samples was smaller in their study (4 vs 8) than in
our study. Therefore, the differences in the control group
resulted in differences in the GO analysis and pathway
analysis.
Several studies have identified biomarkers in stomach can-
cer, and markers matching up with the Lauren classification
strategy have been reported: CDH1, CDX-2, MSI, and
HER2.22 Of these, HER2 is a unique marker that can be used
in the development of targeted agents. The expression of HER2
is more associated with IGC than DGC.23 We also studied the
differentially expressed genes between the 2 groups; however,
we thought that variant genes would play an important role in
the generation of cancer, so we conducted variant analysis first.
For the variant gene analysis, the reliability of the results
increases as the algorithm finds and analyzes genes that have
been previously studied and published, but finding new bio-
marker genes is difficult. All 30 candidate genes identified are
genes that have been published as biomarkers, and studying
whether they are expressed or useful as markers in cancer is
very interesting. However, NUDC has been reported in color-
ectal cancer, but there has been few research in stomach cancer
field. Additionally, the recently studied markers were discov-
ered through a comparative study of normal and cancer tissues
from multiple organs. However, NUDC was discovered
through comparative analysis of 2 subtypes of gastric cancer
with quite different prognoses (signet ring cell gastric cancer,
worst prognosis in diffuse-type and well-differentiated gastric
cancer, best prognosis in intestinal-type).
A mammalian NUDC-like protein has been reported to be
important for cell viability and dynein stability (dyneins are a
family of cytoskeletal motor proteins that move along micro-
tubules in cells).24 The depletion of NUDC is reported to
reduce end-on microtubule attachments at kinetochores and is
one of the causes of chromosomal condensation defects at the
metaphase plate.16 It has been reported that NUDC is required
for Plk1 targeting to the kinetochore and chromosomal con-
densation. Silencing of NUDC using siRNA interferes with
proliferating HeLA cells and affects Caenorhabditis elegans,
and overexpression of NUDC using adenovirus is known to
lead to multinucleation of cells.25
In the cancer field, NUDC overexpression has been reported
to block prostate cancer cell division, and this strategy has been
developed as a targeted therapy.14 NUDC has been reported to
be increased in acute myeloid leukemia, acute lymphocytic
leukemia, chronic myelogenous leukemia, lung cancer, mela-
noma, and prostate cancer.15,17,25,26 In addition, NUDC is
reported to increase the proliferation, migration and invasion
of renal carcinoma cells.17 In the TCGA database-associated
stomach cancer dataset (TCGA-STAD), the mutation rate of
NUDC was 3% (3/440), and the copy number variation (CNV)
gain and loss rates were 1.16% (5/432) and 12.73% (55/432),
respectively. We found an NUDC variant in 2 of 3 samples of
SRC-GC but no variants in 5 WD-GC samples. These NUDC
variants in SRC-GCs might be nonfunctional and nonfunction-
ing of movement of nuclei following mitosis may play an
important role not only in driving SRC-GC, but also in progres-
sion of stomach cancer. We are planning to study the changes
in the function of NUDC according to whether it varies in the
future.
The limitation of this study is the small number (8 samples)
of samples. We could not analyze the relationship between
each NUDC score and survival due to the small number of
samples and the changes in function of NUDC according to
whether it is variant. However, the cancer tissues were dis-
sected by LCM, which produced a more accurate result. The
increased accuracy of LCM was confirmed by IHC analysis in
the large cancer cohort. To the best of our knowledge, there are
few studies comparing the variants and transcriptomes of SRC-
GCs and WD-GCs.
In conclusion, we found 30 gastric cancer driver variants by
comparing SRC-GCs and WD-GCs. NUDC was identified as
one of the cancer driver variants and could be a potential good
prognostic marker in gastric adenocarcinoma.
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